ASKA Pharmaceutical Holdings Co.,Ltd. (TYO:4886)
Japan · Delayed Price · Currency is JPY 2,138.00
+26.00 (1.23%)
Jan 21, 2026, 3:30 PM JST
TYO:4886 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 67,021 | 64,139 | 62,843 | 60,461 | 56,607 | 55,181 | Upgrade | |
Revenue Growth (YoY) | 5.44% | 2.06% | 3.94% | 6.81% | 2.58% | 5.02% | Upgrade |
Cost of Revenue | 34,607 | 32,803 | 32,178 | 31,876 | 30,255 | 29,798 | Upgrade |
Gross Profit | 32,414 | 31,336 | 30,665 | 28,585 | 26,352 | 25,383 | Upgrade |
Selling, General & Admin | 20,746 | 18,972 | 19,436 | 19,249 | 17,958 | 21,773 | Upgrade |
Research & Development | 7,031 | 7,031 | 4,728 | 4,227 | 3,598 | - | Upgrade |
Operating Expenses | 27,777 | 26,003 | 24,164 | 23,476 | 21,556 | 21,773 | Upgrade |
Operating Income | 4,637 | 5,333 | 6,501 | 5,109 | 4,796 | 3,610 | Upgrade |
Interest Expense | -138 | -51 | -40 | -50 | -56 | -59 | Upgrade |
Interest & Investment Income | 340 | 292 | 334 | 338 | 258 | 237 | Upgrade |
Earnings From Equity Investments | -53 | -53 | -41 | - | - | -453 | Upgrade |
Currency Exchange Gain (Loss) | -215 | -123 | -51 | -43 | - | - | Upgrade |
Other Non Operating Income (Expenses) | -39 | -184 | -169 | -70 | -75 | -243 | Upgrade |
EBT Excluding Unusual Items | 4,532 | 5,214 | 6,534 | 5,284 | 4,923 | 3,092 | Upgrade |
Gain (Loss) on Sale of Investments | 127 | 127 | 3,340 | 124 | -1,151 | 491 | Upgrade |
Gain (Loss) on Sale of Assets | 19 | -106 | -13 | -52 | 9,382 | -8 | Upgrade |
Asset Writedown | -300 | -300 | - | - | -5,953 | - | Upgrade |
Other Unusual Items | 1,257 | 1,257 | - | - | -1,038 | - | Upgrade |
Pretax Income | 5,635 | 6,192 | 9,861 | 5,356 | 6,163 | 3,575 | Upgrade |
Income Tax Expense | 713 | 1,091 | 2,316 | 1,118 | 1,873 | 862 | Upgrade |
Earnings From Continuing Operations | 4,922 | 5,101 | 7,545 | 4,238 | 4,290 | 2,713 | Upgrade |
Minority Interest in Earnings | -155 | - | - | - | - | - | Upgrade |
Net Income | 4,767 | 5,101 | 7,545 | 4,238 | 4,290 | 2,713 | Upgrade |
Net Income to Common | 4,767 | 5,101 | 7,545 | 4,238 | 4,290 | 2,713 | Upgrade |
Net Income Growth | -20.23% | -32.39% | 78.03% | -1.21% | 58.13% | 318.03% | Upgrade |
Shares Outstanding (Basic) | 28 | 28 | 28 | 28 | 28 | 28 | Upgrade |
Shares Outstanding (Diluted) | 28 | 28 | 28 | 28 | 28 | 28 | Upgrade |
Shares Change (YoY) | 0.13% | 0.12% | 0.26% | -0.46% | 0.06% | 0.23% | Upgrade |
EPS (Basic) | 168.05 | 179.95 | 266.49 | 150.08 | 151.22 | 95.69 | Upgrade |
EPS (Diluted) | 168.05 | 179.95 | 266.49 | 150.08 | 151.22 | 95.69 | Upgrade |
EPS Growth | -20.33% | -32.47% | 77.57% | -0.75% | 58.03% | 317.09% | Upgrade |
Free Cash Flow | -953 | -475 | 166 | 2,890 | 2,263 | 5,437 | Upgrade |
Free Cash Flow Per Share | -33.60 | -16.76 | 5.86 | 102.34 | 79.77 | 191.76 | Upgrade |
Dividend Per Share | 57.000 | 55.000 | 40.000 | 16.000 | 15.000 | - | Upgrade |
Dividend Growth | 26.67% | 37.50% | 150.00% | 6.67% | - | - | Upgrade |
Gross Margin | 48.36% | 48.86% | 48.80% | 47.28% | 46.55% | 46.00% | Upgrade |
Operating Margin | 6.92% | 8.31% | 10.35% | 8.45% | 8.47% | 6.54% | Upgrade |
Profit Margin | 7.11% | 7.95% | 12.01% | 7.01% | 7.58% | 4.92% | Upgrade |
Free Cash Flow Margin | -1.42% | -0.74% | 0.26% | 4.78% | 4.00% | 9.85% | Upgrade |
EBITDA | 7,253 | 7,580 | 9,163 | 8,236 | 7,681 | 6,915 | Upgrade |
EBITDA Margin | 10.82% | 11.82% | 14.58% | 13.62% | 13.57% | 12.53% | Upgrade |
D&A For EBITDA | 2,616 | 2,247 | 2,662 | 3,127 | 2,885 | 3,305 | Upgrade |
EBIT | 4,637 | 5,333 | 6,501 | 5,109 | 4,796 | 3,610 | Upgrade |
EBIT Margin | 6.92% | 8.31% | 10.35% | 8.45% | 8.47% | 6.54% | Upgrade |
Effective Tax Rate | 12.65% | 17.62% | 23.49% | 20.87% | 30.39% | 24.11% | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.